SEC Tracker
Get the app
NAGE · XBRL financial data

Niagen Bioscience financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (NAGE's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue19,49521,196*22,15322,73925,58029,125*30,48131,11733,98633,839*31,47429,785
Cost of revenue7,5268,259*8,6979,0469,34010,928*11,15010,89112,05812,135*11,49810,471
Gross profit11,96912,937*13,45613,69316,24018,197*19,33120,22621,92821,704*19,97619,314
Research and development1,2411,159*2,0951,3161,2901,315*1,2581,5671,7951,710*1,4811,513
General and administrative5,8405,426*5,3525,6646,3041,055*5,1847,2677,1297,477*7,2446,971
Total operating expenses13,11613,105*14,18713,94914,63811,086*14,55917,04117,69217,618*18,40018,614
Operating income (loss)(1,147)(168)*(731)(256)1,6027,111*4,7723,1854,2364,086*1,576700
Interest income—————year only———year only——
Income tax expense (benefit)—year only000305*168128222292*417106
Net income (loss)(959)114*(492)(15)1,8787,179*5,0633,6094,5784,132*6,318963
Earnings per share, basic USD per share(0.01)0.00*(0.01)0.000.020.09*0.070.050.060.05*0.080.01
Earnings per share, diluted USD per share(0.01)0.00*(0.01)0.000.020.09*0.060.040.050.05*0.070.01
Weighted average shares, basic thousands of shares75,05075,123*75,23075,55975,97276,943*77,81079,24979,77979,845*79,91779,322
Weighted average shares, diluted thousands of shares75,05075,123*75,23075,55977,76883,884*83,23286,24186,61985,613*84,56682,504

Balance sheet

CSV

Fiscal quarters (NAGE's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents26,60027,20027,40027,70032,20044,50055,50060,30064,10064,78866,54966,740
Accounts receivable—5,2346,6047,8187,0967,7687,0529,6568,5069,74113,0688,580
Inventory12,62414,52512,49511,51110,5449,19211,18514,40618,79120,42424,01620,640
Prepaid and other current assets—————————1,312—1,826
Total current assets47,18149,53448,97649,30252,13464,10276,21886,67993,61696,806105,12197,786
Right-of-use asset3,0032,4002,2262,0631,8991,7302,6842,5252,3612,1922,0191,840
Total assets53,48354,96454,07954,03556,52268,27881,33791,52598,139106,406114,329106,589
Accounts payable9,19810,2327,8998,1056,9038,52610,63213,68012,74210,79613,2779,439
Accrued liabilities9,1939,49310,4658,6219,5927,8179,0507,3818,7007,7227,6213,841
Total current liabilities19,44420,62219,45217,86717,69917,94820,83722,32722,71219,91922,82415,050
Lease liability, non-current2,9112,5632,3562,1331,8731,6572,5762,3292,0771,8151,5441,412
Total liabilities26,17526,50825,12823,31722,15322,18425,99227,33027,46329,87331,99924,061
Accumulated deficit(190,574)(190,460)(190,952)(190,967)(189,089)(181,910)(176,847)(173,238)(168,660)(164,528)(158,210)(157,247)
Total stockholders' equity27,30828,45628,95130,71834,36946,09455,34564,19570,67676,53382,33082,528
Total liabilities and equity53,48354,96454,07954,03556,52268,27881,33791,52598,139106,406114,329106,589
Common shares outstanding (cover page) thousands of shares75,12475,30975,53975,93376,38377,75078,77079,75379,80680,08079,64479,126

Cash flows

CSV

Fiscal quarters (NAGE's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(959)114*(492)(15)1,8787,179*5,0633,6094,5784,132*6,318963
Stock-based compensation1,1171,037*9841,185735752*1,0751,4881,7561,748*1,7161,723
Net cash from operating activities396*649*295(264)*3,495*year only7,8831,250*3,692*679*(1,194)2,772*
Net cash from investing activities(26)*(21)*(41)(12)*(21)*(69)*(32)(135)*(24)*(101)*5,245(92)*
Proceeds from issuing common stock—year only——————————
Share repurchases—————year only00*—year only2,3542,767*
Net cash from financing activities(3)*(76)*(14)596*1,039*3,748*3,1053,743*148*(80)*(2,290)(2,489)*
Net change in cash367*552*240320*4,513*12,262*10,9564,858*3,816*498*1,761191*

Compare with peers

SIC 2833 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2833 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Niagen Bioscience66,74029,7852,772*79.1M— 10-QJun 30, 2026
Nurix Therapeutics720,242673,064615,631*109.2M— 10-QAug 31, 2026
Syndax Pharmaceuticals135,94183,298(27,254)*not reported11.9 quarters 10-QSep 30, 2026
Wave Life Sciences197,31513,158(60,142)*197.2M7.4 quarters 10-QSep 30, 2026
Cogent Biosciences181,172not reported(77,271)*173.5M10.3 quarters 10-QJun 30, 2026
Geron62,64357,480(15,827)*642.5M4.0 quarters 10-QJun 30, 2026
uniQure98,4425,196(47,827)*70.1M2.6 quarters 10-QSep 30, 2026
Phibro Animal Health61,419396,747*24,094*not reported— 10-KJun 30, 2026
Intellia Therapeutics106,1287,659(83,113)*140.1M5.3 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.